Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of Darzalex®▼ (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
Subcutaneous formulation also showed reduced administration time and lower rates of infusion-related reactions compared to intravenous administration BEERSE, Belgium–(BUSINESS WIRE)–The…